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ABSTRACT
Tuberous sclerosis complex (TSC) is an autosomal dominant disorder caused by mutations in either TSC1 or TSC2. TSC has high
frequency of osseousmanifestations such as sclerotic lesions in the craniofacial region. However, an animalmodel that replicates TSC
craniofacial bone lesions has not yet been described. The roles of Tsc1 and the sequelae of Tsc1 dysfunction in bone are unknown. In
this study, we generated a mouse model of TSC with a deletion of Tsc1 in neural crest-derived (NCD) cells that recapitulated the
sclerotic craniofacial bone lesions in TSC. Analysis of this mouse model demonstrated that TSC1 deletion led to enhanced mTORC1
signaling in NCD bones and the increase in bone formation is responsible for the aberrantly increased bone mass. Lineage mapping
revealed that TSC1 deficient NCD cells overpopulated the NCD bones. Mechanistically, hyperproliferation of osteoprogenitors at an
early postnatal stage accounts for the increased osteoblast pool. Intriguingly, early postnatal treatment with rapamycin, an mTORC1
inhibitor, can completely rescue the aberrant bone mass, but late treatment cannot. Our data suggest that enhanced mTOR
signaling in NCD cells can increase bone mass through enlargement of the osteoprogenitor pool, which likely explains the sclerotic
bone lesion observed in TSC patients. © 2015 American Society for Bone and Mineral Research.
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Introduction
Tuberous sclerosis complex (TSC) is a genetic disordercharacterized by the presence of benign congenital tumors
in multiple organs. TSC is due to the loss of TSC1 (harmartin) or
TSC2 (tuberin) and subsequent hyperactivation of the mamma-
lian/mechanistic target of rapamycin complex 1 (mTORC1),(1) a
conserved signaling node that integrates intracellular and
extracellular cues to control many biological processes, includ-
ing protein and lipid synthesis and autophagy.(2) The TSC1-TSC2
complex is a key upstream regulator of mTORC1 and functions
as a GTPase-activating protein (GAP) for the Ras homolog
enriched in brain (Rheb) GTPase. The GTP-bound form of Rheb
directly interacts with mTORC1 and stimulates its kinase activity.
As a Rheb GAP, the TSC1-TSC2 complex converts Rheb into its
inactive GDP-bound state and negatively regulates mTORC1.(3)
Osseous manifestations of TSC include cyst-like lesions,
hyperostosis of the inner table of the calvaria, and excess
periosteal bone formation. The frequency of abnormal sclerotic
islands in the craniofacial region is approximately 40% and
radiographic changes in the hands or feet is about 66%.(4)
Besides the localized sclerotic lesions, TSC patients may have
marked thickening of frontal bones, mandibles and maxilla,
which are all neural crest derived.(5) The high frequency of
osseous manifestations in TSC patients highlights the impor-
tance of elucidating how mTOR signaling regulates bone
metabolism in vivo.
Geneticmousemodels are useful tools to determine the in vivo
roles of signalingpathways. Disruptionof the TSC1-TSC2 complex
through the loss of either Tsc1 or Tsc2, results in constitutive
activation of mTORC1. Therefore, ablation of Tsc1 or Tsc2 offers a
genetic means to produce mTORC1 gain-of-function models to
mimic the congenital TSC disorder. However, the early embryonic
lethality of the Tsc1 or Tsc2 knockout (KO) mice prevents us from
studying themechanismsbywhichdysregulatedmTOR signaling
affects postnatal bone metabolism.(6–8) Recently, it was reported
that Tsc2 deletion in mature osteoblasts leads to increased
osteoblast number and a progressive increase in postnatal bone
acquisition through undefined mechanisms.(9) The roles of
mTORC1 signaling in early osteoblasts and in cranial neural
crest-derived cells are unknown. In this study, we generated
conditional KO (CKO) mice to delete Tsc1 specifically in neural
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crest-derived (NCD) cells. NCD cells contribute to the formation of
a majority of the craniofacial bones such as the frontal, nasal and
zygomatic bones.(10) Interestingly, our mouse model recapit-
ulates the sclerotic craniofacial bone lesions seen in TSC patients.
In TSC patients, the deactivation of Tsc1 or Tsc2 likely happens in
early lineage cells. Thus, this model provides a unique
opportunity to explore the mechanisms governing the craniofa-
cial bone lesions in TSC patients. We demonstrated that the
increased bone mass can be rescued by rapamycin treatment at
an early but not a late postnatal stage. Mechanistically, mTORC1
hyperactivation by Tsc1 deletion in neural crest-derived cells led
to expansion of the osteoprogenitor pool through enhanced
proliferation at an early postnatal stage.
Materials and Methods
Mice
The floxed Tsc1 (Tsc1flox/flox), P0-Cre (line A), Rosa 26 transgenic
mice were described previously.(8,11,12) Tsc1flox/flox mice were
mated with P0-Cre mice to generate Tsc1flox/flox;P0-Cre mice and
Tsc1flox/þ;P0-Cre mice, designated as CKO and cHet mice
respectively. Tsc1flox/flox mice were served as a control for CKO
mice. Tsc1flox/flox mice were bred with Rosa 26 reporter mice to
generate Tsc1flox/flox;Rosa/Rosa mice that introduce the LacZ
reporter gene. Then, cHet mice were bred with Tsc1flox/flox;Rosa/
Rosa mice to generate Tsc1flox/þ;P0-Cre;Rosa/þ (cHet-LacZ) and
Tsc1flox/flox;P0-Cre;Rosa/þ (CKO-LacZ) mice. The P0-Cre trans-
genic strain was initially generated on the FVB background(11)
and then backcrossed onto the 129S1/SvJ background. P0-Cre
transgenic mice were crossed to Tsc1flox/flox mice that were
maintained on the C57BL/6 background. The Rosa26-LacZ allele
was maintained on the mixed 129S1/SvJ and C57BL/6 back-
grounds. For some experiments, P0-Cre transgenic mice were
backcrossed onto C57BL/6 background for at least 5 gener-
ations. The 129S1/SvJ/C57BL/6 mixed background and more
pure C57BL/6 background showed similar sclerotic phenotypes
in CKO mice. All experimental procedures were carried out with
the approval of the Institutional Animal Care andUse Committee
at the University of Michigan.
X-gal staining and FACS-galactosidase assay
Skulls were fixed in 4% PFA for 15min at room temperature,
followed by three PBS washes for 5min each. Skulls were then
stained in 2ml LacZ staining solution (Kferri/Kferro 5mM, MgCl2
2mM, X-gal 1mg/ml, NP-40 0.02%, SodiumDeoxycholate 0.01%) at
37 °C for 8h. Stained skulls werewashed 3 timeswith PBS and then
post-fixed in 4% PFA overnight at 4 °C. Skulls were decalcified and
embedded in paraffin; 6mM sections (described below) were
counterstainedwithNeutral Red. Primary calvarial osteoblastswere
digested from frontal and nasal bones (described below) and
grown on glass coverslips overnight. Cells were fixed in 4% PFA
with 0.4% glutaraldehyde at room temperature for 5min and
washed 3 times with PBS. Cells were stained in 1ml LacZ staining
solution for 5–8h, then washed 3 times with and mounted with
ProLong1 Gold Antifade Reagent with DAPI (Life Technologies,
P36931). LacZ positive cell number and bone perimeter were
quantified with the multipoint tool and segmented line measure-
ment function of Image J software. Expression of LacZ in live cells
was examined using fluorescein di-b-d-galactopyranoside (Fluo-
Reporter LacZ Flow Cytometry Kit; Molecular Probes) staining
according to the manufacturer’s instructions. Cells were analyzed
on a FACSCanto (BD Biosciences) instrument.
RNA extraction and qRT-PCR
Total RNA was isolated using Trizol reagent (Invitrogen)
according to the manufacturer’s instructions. qRT–PCR analyses
were performed as described previously.(13) cDNA templates
were subjected to qPCR using the SYBRGreen PCR Core reagents
system (Qiagen). 18S rRNA was used as an internal control.
Relative gene expression was calculated by the DCT (the
difference between the threshold cycles) method.(14) Primer
sequences used for real-time PCR are available upon request.
Western blot analysis
Protein extractswere prepared fromcalvaria of 7-day-old postnatal
mice. Primary calvarial osteoblasts were isolated from neonatal
mice (between birth and postnatal day 3). Cells and tissues were
lysed using NP40 lysis buffer (PH 8.0 Tris-HCl 20mM, NaCl 137mM,
1% NP40, 10% Glycerol, Na3VO4 1mM) and protein extracts were
analyzed by 8% (TSC1, Vinculin) and 15% (p-S6, S6) SDS–PAGE and
blotted onto PVDF membrane (Millipore, IPVH00010). Membranes
were incubated with rabbit anti-TSC1 antibody (Cell signaling,
#4906), rabbit anti-p-S6 antibody (Cell Signaling, #5364), rabbit
anti-S6 antibody (Cell signaling #2217) or mouse anti- Vinculin
antibody (Sigma-aldrich V4505), followed by a horseradish
peroxidase-conjugated secondary antibody (Goat anti-rabbit,
Thermo, 31460) and aGoat anti-mouse antibody (Jacksonimmuno,
115–035-072).MembranesweredevelopedwithHPR substrate ECL
(Millipore, WBKL S0500). Films were scanned using an Epson
Perfection V700 photo system and bands were quantifiedwith the
optical density function of Image J software.
Histology
Skulls were decalcified in 14% EDTA solution at 4 °C, then
processed using a Leica ASP 300 paraffin tissue processor and
embedded in paraffinwith Tissue-Tek paraffin tissue embedding
station. 6mM sections were cut with a Leica RM 2145 microtome
and used for H&E staining or immunostaining.
Immunostaining
Paraffin sections were de-waxed and rehydrated in xylene and
sequential alcohol solutions. Antigen retrieval was performed
according to instructions for each antibody. For immunohis-
tochemistry, endogenous peroxidase was blocked by 0.3%
H2O2/ Methanol for 30min. Sections were then incubated with
primary antibodies (anti-p-S6 and anti-Osterix) overnight at 4 °C.
A horseradish peroxidase–streptavidin system (Dako) was used
to detect immunoreactivity, which was followed by counter-
staining with hematoxylin (Sigma-Aldrich). For immunofluor-
esence, sections were incubated with primary antibody (Ki67,
Spring, M306) overnight at 4 °C after rehydration, washed 3
times with PBST, and then incubated with secondary antibody
(Life Technologies, A-21206) for 1 h at room temperature. After 3
washes, sections were mounted with ProLong1 Gold Antifade
Reagent with DAPI. Positive cells and bone perimeter were
quantified with the multipoint tool and segmented line
measurement function of Image J software.
Micro CT
Skulls were dissected free of soft tissue and analyzed by
microcomputed tomography using an eXplore Locus SP (GE
Healthcare Pre-Clinical Imaging, London, ON, Canada) as we
described previously.(15–17)
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Calvaria thickness measurement
Calvaria thickness was measured as described previously.(13) In
brief, the measurements were performed at the center of the
frontal and parietal bones with a caliper (Pfingst, Sweden) on 1-
month, 2-month, 3-month, and 1-year-old mice in a blinded
manner.
Histomorphometry
Static and dynamic histomorphometry were performed similar
to what we described previously.(18–20) For dynamic histo-
morphometry, mice were given intraperitoneal injections of
calcein (10mg/kg) 6 days and 2 days prior to sacrifice.
Measurements were made on the frontal bones. All static and
dynamic parameters were measured according to the Report of
the American Society of Bone and Mineral Research Histo-
morphometry Nomenclature Committee.(21)
Primary calvarial osteoblast isolation and culture
Calvarial cells were isolated from1- to 3-day-old transgenicmice.
After removal of sutures, frontal and nasal bones were subjected
to four sequential digestions as previously described.(13) Cells
were plated at a density of 1.9–2.4 104 cells/cm2 in 6-cmdishes
in alpha MEM containing 10% FBS. For osteogenic differentia-
tion, the medium was changed to differentiation medium after
1 week of culture as described previously.(13)
Rapamycin rescue experiments
Rapamycin (LC laboratory) was reconstituted in absolute
ethanol at 10mg/ml and diluted in 5% Tween-80 (Sigma-
Aldrich) and 5% PEG-400 (Hampton Research). Mice received
1mg/kg rapamycin by i.p. injection every other day. Mice were
treated from birth to one-week-old for LacZ staining and
western blotting, from one week-old to two-months-old and
from 1-month-old to 3-months-old for calvaria thickness
measurements.
Statistical analysis
Student’s t test was used to compare two groups. Differences
were considered significant at P< 0.05.
Results
Targeting a Tsc1 mutation into neural crest cells during
craniofacial bone development
To establish a mouse model mimicking the craniofacial bone
lesions in TSC patients, we generated neural crest-specific Tsc1
mutant mice. We previously established a Cre transgenic strain
under the control of the P0 promoter (P0-Cre), which targets
neural crest cells and expresses Cre in approximately 30% of
neural crest-derived nerve cells.(11,22) We crossed P0-Cre
transgenic mice to Rosa26-LacZ Reporter mice that allows us
to examine Cre recombinase activity by expression of the b-
galactosidase (b-gal) gene.(12) P0-Cre-mediated recombination,
revealed by X-gal staining, was detected in neural crest and its
derived tissues in cranialfacial regions but not in limb at early
embryonic stages.(22) With the same approach, we showed that
P0-Cre mediated recombination was detected in neural crest-
derived nasal and frontal bones but not in mesoderm-derived
parietal bones (Fig. 1A). Of note, the staining pattern was very
sporadic and most areas were not stained, indicating that only a
small proportion of neural crest-derived cells were targeted by
P0-Cre. To inactivate Tsc1 during craniofacial bone develop-
ment, we bred P0-Cre transgenic mice to Tsc1flox/flox mice(8) and
subsequently generated Tsc1 mutantmice with the genotype of
Tsc1flox/flox;P0-Creþ (hereafter, CKO).
CKO mice were born at the expected Mendelian ratios and
had comparable body weight compared to their Tsc1flox/flox;P0-
Cre- (hereafter, CTR) littermates (Fig. S1). Despite the very
sporadic expression pattern of P0-Cre in frontal and nasal bones
(Fig. 1A), TSC1 protein in cell lysates prepared from the neural
crest-derived nasal and frontal bones of CKO mice was reduced
by 60% compared to CTR (Fig. 1B, 1C). As expected, mTORC1
signaling, as shown by the expression of phosphorylated S6 (a
ribosomal protein that is a downstream target of mTORC1
signaling), was increased in nasal and frontal bones from CKO
mice (Fig. 1B, 1D). Similarly, there was much stronger
phosphorylated S6 staining in the osteoblasts of frontal bones
from CKO mice (Fig. 1E). In addition, there were more
phosphorylated S6 positive cells in the extracranial periosteum
of frontal bones from CKO mice (Fig. 1F).
Deletion of TSC1 in neural crest derived cells leads to
higher craniofacial bone mass
Similar to the sclerotic lesion in TSC patients who have either a
TSC1 or TSC2 mutation, CKO mice displayed thickened neural
crest-derived frontal and nasal bones at one month of age.
Three-dimensional microcomputed tomography (microCT) and
reconstruction of the skull confirmed this observation (Fig. 2A).
CKO mice had a significantly greater amount of neural crest-
derived bones including frontal calvaria, zygomatic bones, and
nasal bones. Cross sectional analysis demonstrated that the
thickness of frontal bones (neural crest-derived), but not parietal
bones (mesoderm-derived), increased in CKO mice (Fig. 2B). Of
note, the thickened bone in CKO mice appeared to have higher
mineral density illustrated by their dense appearance compared
to the porous appearance of control bones using an arbitrary
threshold for mineralized tissue (Fig. 2A). Quantitative measure-
ments showed that there was a lifelong accumulation of neural
crest-derived craniofacial bone mass in CKO mice (Fig. 2C).
Calvaria from mice heterozygous for the conditional Tsc1 allele
(Tsc1flox/þ;P0-Creþ, hereafter cHet) had a similar thickness
compared to calvaria from CTR mice (Fig. S2), indicating that
TSC1 haploinsufficiency does not affect neural crest-derive bone
acquisition. In addition, P0-Cre mice had similar frontal bone
thickness compared to wild type controls (Fig. S3), indicating
that P0-Cre itself did not cause the sclerotic phenotype.
High bone mass phenotype of the TSC1-deficient mice is
due to increased osteoblast bone formation ability but
not altered osteoclastogenesis
As a first step to determine the underlying mechanism of the
high bonemass phenotype in CKOmice, histomorphometry was
performed in frontal bone of one-month-old CTR and CKOmice.
The bone formation rate (BFR) in CKO mice was increased on
both the extracranial and intracranial surfaces (Fig. 3A-3G). On
the extracranial surface, the BFR increase was a result of an
elevated mineral apposition rate (MAR) without a change in
mineralizing surface (MS/BS) (Fig. 3B-3D). On the intracranial
surface, the BFR increase was the combinational effect of
increases in both the MAR and MS/BS (Fig. 3E-3G). To determine
whether altered osteoclastogenesis may contribute to the high
bone mass, we performed TRAP staining on the frontal bones
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and quantified the osteoclast parameter at different regions
(extracranial, intracranial and bonemarrow surfaces) and did not
find any alterations (Fig. 3H). In line with the unaltered osteoclast
number, Receptor activator of nuclear factor kappa-B ligand
(Rankl) and Osteoprotegerin (Opg) mRNA levels were not
changed in CKO frontal bones (Fig. 3I). Altogether, these data
indicate that the high bone mass phenotype in CKO mice is due
to enhanced osteoblast bone formation and is not secondary to
altered osteoclastogenesis.
TSC1 deletion in neural crest-derived cells leads to
increased osteoblast populations
The moderate to high TSC1 deletion efficiency in neural crest-
derived bones from CKO mice compared to the very low level
of P0-Cre expression (Fig. 1A-1C) prompted us to hypothesize
that TSC1 null osteoblasts may overpopulate neural crest-
derived bones. To test this hypothesis, we performed lineage
mapping experiments by introducing the Rosa26-LacZ report-
er into CTR and CKO mice. Tsc1flox/þ;P0-Creþ;Rosa26/þ
(hereafter, cHet-LacZ) and Tsc1flox/flox;P0-Creþ;Rosa26/þ (here-
after, CKO-LacZ) mice were analyzed by X-gal staining to
determine the effect of TSC1 deletion in neural crest stem/
progenitor cells on neural crest-derived cell populations.
Consistent with the X-gal staining pattern seen in P0-Cre mice
mated with R26R mice (Fig. 1A), there was sporadic X-gal
staining in the frontal and nasal bones of cHet-LacZ mice
(Fig. 4A). In contrast, intense X-gal staining was observed in
the similar areas of CKO-LacZ mice. There were many more
LacZþ cells in the cranial periosteum of the frontal bone of
CKO-LacZ mice (Fig. 4B-4D). To further characterize the effect
of TSC1 deletion on LacZþ osteoblast number, we cultured
primary osteoblasts isolated from the neural crest-derived
frontal and nasal bones from both cHet-LacZ and CKO-LacZ
Fig. 1. TSC1 deletion in osteoblasts with P0-Cre leads to increasedmTORC1 activity in neural crest-derived osteoblasts. (A) X-gal staining of skulls of one-
week-old P0-Cre-;Rosa26 and P0-Creþ;Rosa26 mice. P¼parietal bone; F¼ frontal bone; N¼nasal bone. (B) Immunoblotting analysis of TSC1, p-S6, S6
and Vinculin protein level in frontal and nasal bones of one-week-old CTR and CKO mice. (C, D) Quantification of TSC1 (C) and p-S6 (D) protein level,
normalized to Vinculin and S6 respectively. #p<0.001, n¼ 5 per group. (E) Immuno-staining of p-S6 in frontal bone of one-month-old CTR and CKOmice.
Arrows point to p-S6þ cells. Scale bar¼ 40mm. (F) Quantification of p-S6 positive cell number per bone perimeter at the frontal bone extracranial
periosteum of one-month-old CTR and CKO mice. p<0.05, n¼ 5 per group. For C, D, and F, the data were presented as mean SD.
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mice. Consistent with the in vivo staining pattern, there was
more than a two-fold increase in the percentage of LacZþ cell
in the CKO-LacZ cultures (Fig. 4E-4F). The fluorescein di-b-d-
galactopyranoside (FDG) based flow cytometry analysis also
showed an increased number of LacZþ osteoblasts in CKO
cultures (Fig. S4). The increased number of LacZþ cells in CKO
mice strongly supports the notion that TSC1 null neural crest-
derived cells overpopulated neural crest-derived bones. To
directly determine whether there was increased osteoblast
population in vivo, we performed immunostaining on the
frontal bones with an Osterix (an osteoblast specific marker)
antibody. As expected, there were more Osterixþ osteoblasts
in the neural crest-derived bones of CKO mice (Fig. 4G, 4H). In
addition, we found an increase in osteocyte density in neural
crest-derived frontal bones from CKO mice (Fig. 4I, 4J).
Altogether, these data indicate that Tsc1 deletion by P0-Cre
leads to increased osteoblast lineage cells.
Deletion of TSC1 increases the proliferation of
osteoprogenitors without affecting in vivo osteoblast
differentiation
To determine the cellular mechanism that may be responsible
for the increased osteoblast populations, we performed
immunofluorescence staining with Ki67 (a proliferation marker).
We observed a dramatic increase in proliferation in the
periosteum of the frontal bones of one-week-old CKO mice
(Fig. 5A, 5B). In line with the enhanced proliferation, we also
observed an increase in the expression of Cyclin D1, a critical
target of proliferative signals in the G1 phase of the cell cycle
(Fig. 5C). Interestingly, we did not find an alteration of
proliferation at one month of age (Fig. S5A-S5C). As a first
step to determine themolecularmechanism bywhich enhanced
mTORC1 signaling increases osteoprogenitor proliferation, we
examined the canonical Wnt signaling target gene expression in
neural crest-derived bones. We found similar mRNA expression
of Axin 2 (Axin2), Gap junction protein, alpha 1, 43kDa (Gja1, also
known as Cnx43), Collagen, type VI, alpha 1(Col6a1), Matrix
Metallopeptidase 16 (Mmp16) in mutant and control bones,
indicating that the pro-proliferative effect of TSC1 deletion in
neural crest-derived cells was not mediated by Wnt signaling
(Fig. 5D).
To determine whether enhanced osteoblast differentiation
may contribute to the high bone phenotype, we measured the
mRNA expression of osteoblast differentiation related genes. We
found no differences in themRNA expression of Collagen, type I,
alpha 1 (ColIa1), Alkaline phosphatase, liver/bone/kidney (Alpl),
Runt-related transcription factor 2 (Runx2), Sp7 transcription
factor (also known as Osterix, Osx), Activating transcription
factor 4 (Atf4), Bone sialoprotein (Bsp), and Bone gamma
carboxyglutamate protein (also known as Osteocalcin, Ocn) in
the cranial bones of CKO and CTRmice (Fig. 5E and Fig. S5D). The
Fig. 2. TSC1 deletion by P0-Cre leads to increased neural crest-derived bone mass. (A) MicroCT images of skulls of 1-year-old CTR and CKO mice.
P¼parietal bone; F¼ frontal bone; Z¼ zygomatic bone; N¼nasal bone. (B) Coronal section view of the frontal and parietal bone of skulls shown in (A).
(C) Thickness of frontal and parietal bones of CTR and CKOmice at 1-, 2-, 3-month and 1-year-old. p<0.05, n¼ 15–19 for 1-month-old samples; n¼ 19–23
for 2-month-old samples; n¼ 10–19 for 3-month-old samples; n¼ 5–7 for 1-year-old samples. Data were presented as mean SD.
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only molecular abnormality observed in the frontal/nasal bones
of CKO mice was an increase in the expression of Osteocalcin, a
gene whose inactivation or overexpression does not affect ECM
mineralization.(23,24) In addition, we determined the in vitro
differentiation of TSC1 null primary osteoblasts isolated from
frontal and nasal bones (Fig. S6). As expected, there was
increased p-S6 expression when TSC1 was efficiently deleted
(Fig. S6A). Mineralization in CKO cultures was compromised
compared to control cultures (Fig. S6B) and the mRNA
expression of osteoblast differentiation related genes was
generally decreased (Fig. S6C). Taken together, these data
suggest that the high bone mass phenotype in CKO mice is due
to increased osteoblast progenitor proliferation but not
enhanced differentiation.
Fig. 3. Loss of TSC1 increases bone formation. (A) Representative calcein double labeling images of the frontal bone (5 days apart between two
labelings). Scale bar¼ 50mm. (B–G) Dynamic histomorphometry for the extracranial surface (B–D) and intracranial surface (E–G) of frontal bone of one-
month-old CTR and CKOmice: (B, E) mineralizing surface; (C, F) mineral deposition rate (MAR); (D,G) bone formation rate (BFR). (H) Osteoclast number per
bone perimeter of frontal bone of one-month-old CTR and CKO mice. Region A: extracranial surface; Region B: Intracranial surface; Region C: bone
marrow cavity surface. All region: region A, B, and C. (I, J) Quantitative-PCR analysis of the Rankl (I) and Opg (J) mRNA expression in frontal bone of one-
month-old mice. p<0.05, #p<0.001, n¼ 5–6 per group for B-H, n¼ 10 per group for (I) and (J). Data were presented as mean SD.
1200 FANG ET AL. Journal of Bone and Mineral Research
Rapamycin treatment at an early postnatal stage rescues
the aberrantly increased bone mass of TSC1-deficient
mice
TSC1 is a known negative regulator of mTOR activity and our
data show upregulation of mTORC1 signaling in neural crest-
derive bones from CKOmice (Fig. 1B, 1E). To determine whether
upregulated mTORC1 signaling is responsible for the high bone
mass phenotype, we treated CKO and CTR mice with rapamycin
(a widely usedmTORC1 inhibitor) every other day starting at one
week and ending at two months of age (Fig. 6A). Rapamycin
treated mice had decreased body weight compared to vehicle
treated mice (Fig. S7). Strikingly, the increase in frontal bone
thickness in CKO mice was completely prevented, suggesting
that enhanced mTORC1 signaling caused the increased bone
formation. Furthermore, we treated one-day-old cHet-LacZ and
CKO-LacZ mice with rapamycin every other day and analyzed
the X-gal staining pattern at one week of age. In contrast to the
intense X-gal staining observed in the neural crest-derived
bones of untreated CKO-LacZ mice (Fig. 4A), rapamycin
treatment significantly diminished X-gal staining to a level
comparable to cHet-LacZ mice (Fig. 6B). As expected, rapamycin
treatment diminished the increased mTORC1 signaling in the
frontal/nasal bones of CKO mice (Fig. 6C).
Because we observed increased osteoprogenitor proliferation
at one-week-old but not at one-month-old, we reasoned that
TSC1 deletion in neural crest-derived cell may have a transient,
early effect on osteoprogenitor proliferation. Thus, the increased
bone mass phenotype at later postnatal stages may be
determined by this early event. To test this hypothesis, we
treated mice with rapamycin starting at one month of age until
three months of age (Fig. 6D). Interestingly, late rapamycin
treatment did not prevent the increased frontal bone thickness,
supporting the notion that an early event (e.g. osteoprogenitor
pool expansion) is mainly responsible for the high bone mass
phenotype.
Discussion
As the distinguishing features of TSC in humans are predomi-
nantly neurological, a skeletal examination is not necessarily
Fig. 4. TSC1 deletion by P0-Cre leads to increased neural crest derived osteoblasts. (A–D) X-gal staining of skulls of one-week-old Tsc1flox/þ;P0-Cre;Rosa/
þ (cHet-LacZ) and Tsc1flox/flox;P0A-Cre;Rosa/þ (CKO-LacZ) mice. (A) Representative whole skull image after staining. (B) Coronal section of frontal bones,
counter-stained with neutral red. Scale bar¼ 40mm. Arrows point to LacZ positive cells. (C–D) LacZ positive cell number per bone perimeter (C) and
percentage of LacZ positive cells (D) in the periosteum areas shown in B. n¼ 4 per group. (E, F) X-gal staining of primary osteoblasts isolated from frontal
bones of newborn cHet-LacZ and CKO-LacZ mice. (E) Representative X-gal staining images. Red (converted from Dapi staining) indicates nucleus and
blue shows LacZ positive signal. Scale bar¼ 200mm. (F) Percentage of LacZ positive cells. Datawere the average of three independent experiments. (G–H)
Immuno-stainingwith anti-Osterix antibody and quantification of Osterix positive cell per bone perimeter in frontal bone of one-month-old CTR and CKO
mice. n¼ 5 per group. Scale bar¼ 50mm. (I) H&E staining images of frontal bones of one-month-old CTR and CKOmice. Arrows point to osteocytes. Scale
bar¼ 20mm (J) Quantitative analysis of osteocyte number per bone area. p<0.05, #p<0.001, n¼ 5–6 per group. Data were presented as mean SD.
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performed in all cases of TSC. However, the skeletal involvement
of this disease in the skull, hands and feet is well-docu-
mented.(4,25) Of note, 40% of the TSC patients have sclerotic
bone in the cranial vault and sclerotic islands often appear in the
calvarium. Our mouse model successfully recapitulates the
sclerotic bone lesion in TSC patients. However, it is different from
the skeletal manifestation inmost patients in that we observed a
generalized thickening of the targeted neural crest derived skull
bones but not the isolated sclerotic bone lesions seen in most
TSC patients. This likely reflects the fact that loss of
heterozygosity only occurs in a subset of cells in patients.
Besides the isolated sclerotic bone lesions, a case report
demonstrated a more uniformed thickening of neural crest
derived facial bones including frontal bones and mandible.(5)
This may reflect TSC1 or TSC2 loss of heterozygosity (second-hit)
in a subset of cranial neural crest stem cells, which produce a
greater number of progeny that manifest a more severe clinical
phenotype as indicated in loss of heterzygosity of Neuro-
fibromin 1 in neural stem cells.(26) In our mouse model, the null
mutation exists in all targeted cells, producing more uniform
sclerotic lesions. To our knowledge, this is the first mouse model
mimicking the skull sclerotic bone lesions in TSC patients.
Fig. 5. TSC1 deletion leads to increased osteoprogenitor cell proliferation at early postnatal stage. (A, B) Immunofluorescence staining with anti-Ki67
antibody was performed in the frontal bone of one-week-old CTR and CKO mice. (A) Representative fluorescent images in the extracranial periosteum
area. Scale bar¼ 50mm. (B) Ki67 positive cell number per bone perimeter. p<0.05, n¼ 5 per group. (C–E) Quantitative-PCR analysis of the mRNA
expression of cell cycle G1/S transition gene Cyclin D1 (C), Wnt signaling target genes: Axin2, Gja143, Col6a1, Mmp16 (D), and osteoblast differentiation
markers: Col1a1, Alpl, Runx2, Osx, Atf4, Bsp, Ocn (E) of frontal bone of one-week-old CTR and CKO mice. #p<0.001, n¼ 11–12 per group. Data were
presented as mean SD.
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Fig. 6. Early but not late rapamycin treatment can rescue the increased frontal bone thickness in CKO mice. (A) Frontal bone thickness of CTR and CKO
mice at two-month-old after 1mg/kg rapamycin/vehicle i.p injection every other day starting from one-week-old. p<0.05, n¼ 8–18 per group. (B)
Representative pictures of X-gal stained skulls of one-week-old cHet-LacZ and CKO-LacZmice after 1mg/kg rapamycin injection every other day starting
at one-day-old. (C) Immunoblotting analysis of p-S6, S6 and Vinculin protein level in frontal and nasal bones of one-week-old CTR and CKO mice after
1mg/kg rapamycin/vehicle injection every other day starting at one-day-old. Short/longmeans short/long time film exposure. (D) Frontal bone thickness
of CTR and CKO mice before rapamycin treatment at one-month-old and after two months treatment (1mg/kg i.p injection every other day starting at
one-month-old) at three-month-old. p<0.05, n¼ 6–12 per group. (E) Schematic diagram of themechanism bywhich neural crest-specific TSC1 deletion
leads to sclerotic craniofacial bone lesion: Up-regulated mTORC1 signaling (indicated by upward pointing arrow) resulting from TSC1 deletion in neural
crest-derived cells promotes osteoprogenitor expansion (indicated by plus sign) at early postnatal stage. Enlarged osteoprogenitor pool generatesmore
osteoblasts to form thicker bone in CKO mice.
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It is known that mTORC1 can positively regulate cell
proliferation.(27) Activation of the mTORC1 pathway by disrupt-
ing Tsc2 induces quiescent fibroblasts to reenter the cell cycle(28)
and promotes pancreatic b cell proliferation.(29) On the other
hand, overexpression of Tsc1 or Tsc2 attenuates cell prolifera-
tion.(30,31) In this study, we found that upregulated mTORC1
signaling by Tsc1 deletion led to enhanced osteoprogenitor
proliferation. Interestingly, this enhancement was developmen-
tal stage-dependent. Enhanced proliferation was observed at
one week but not at one month of age. Furthermore, we found
increased Cyclin D1 expression at one week but not at one
month of age. Although the detailed molecular mechanism of
this development stage-dependent regulation of proliferation is
currently unknown, it suggests that development stage is an
important determinant of mTORC1’s function on osteoproge-
nitor proliferation. It was suggested that TSC1/TSC2 complex
may regulate Cyclin D1 expression through canonical Wnt/b-
catenin signaling.(32) To determine whether the effect of Tsc1
deletion on regulation of Cyclin D1 expression and osteopro-
genitor proliferation was mediated through Wnt/b-catenin
signaling, we examined the expression of known osteoblast
Wnt/b-catenin target genes. However, we found comparable
Wnt target gene expression in mutant and control bones. This
suggests that TSC1 does not regulate osteoblast progenitor cell
proliferation through Wnt/b-catenin signaling pathway in this
context. The molecular mechanism by which TSC1 deletion
regulates osteoblast progenitor cell proliferation remains to be
determined.
Previous reports demonstrated conflicting results about the
roles of mTORC1 signaling in osteogenic differentiation. Both
stimulatory and inhibitory effects of mTOR inhibition (with
rapamycin) on in vitro osteoblast differentiation were seen
depending on cell types and treatment conditions.(33–40) A
recent study demonstrated that TSC2 deletion in primary
calvarial osteoblast leads to compromised osteoblast differenti-
ation.(9) However, it is unclear whether TSC2 deletion affected
the osteoblast differentiation in vivo. Similar to TSC2 null
cultures, we showed that primary calvarial osteoblast differenti-
ation was compromised in TSC1 null cultures. However, we did
not find alterations in osteoblast differentiation marker gene
expression in CKO bones in our study, suggesting that alteration
in osteoblast differentiation is not the major pathological
mechanism for the cranial bone lesion in our mouse model.
One interesting finding of this study is that rapamycin rescued
the sclerotic bone lesions when mice were treated at an early
postnatal stage but not after one month of age. This suggests
that the cause of the sclerotic bone phenotype had already been
established and become stable at one month of age. Rapamycin
treatment after one month of age could not prevent the already
established change. Importantly, this early change led to the
increased osteoblast number and a sustained increase in bone
thickness during the lifetime of CKO mice. Based on these
findings, we are tempted to hypothesize that up-regulated
mTORC1 signaling in neural crest cells enlarges the osteopro-
genitor/osteogenic stem cell number during an early postnatal
stage and that this is responsible for the increased osteoblast
number and increased bone mass acquisition at later postnatal
stages (Fig. 6E). At one month of age, the expanded
osteoprogenitor/osteogenic stem cell pool has been established
and the maintenance of this pool does not require sustained
mTORC1 activity. Thus, late rapamycin treatment could not
prevent enhanced bonemass acquisition in CKOmice. Although
our data fits well with the aforementioned hypothesis, the
unavailability of the in vivo osteoprogenitor/osteogenic stem
cell markers prevented us from testing this hypothesis directly.
Interestingly, we observed increased proliferation in cranial
periosteum (rich in osteoprogenitors) in CKO mice at an early
but not a late postnatal stage. This supports the notion that up-
regulated mTORC1 signaling promotes the expansion/prolifera-
tion of osteoprogenitors. Thus, the early treatment of rapamycin
could effectively prevent the expansion of the osteoprogenitor
pool and the increased osteoblast number and bone acquisition
but the late treatment could not. This has important biological
and clinical implications. Biologically, it suggests that osteopro-
genitor pool is established early and can determine bone mass
at later stages. Clinically, it suggests that a critical treatment
window may need to be identified for the efficacious treatment
of TSC patients.
In summary, we established a mouse model mimicking the
craniofacial bone lesions in TSC patients. Our findings suggest
that increased bone formation is responsible for the sclerotic
bone lesions. UpregulatedmTORC1 signaling in neural crest cells
can expand osteoprogenitor pool at an early postnatal stage by
promoting proliferation. Rapamycin treatment at a specific time
window can prevent progression of the sclerotic bone lesions.
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